QF
MDGL icon

QVT Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

QVT Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-50,008
Closed -$11M – 82
2013
Q3 		$11M Sell
50,008
-19,449
-28% -$4.14M 0.75% 38
2013
Q2 		$12.1M Buy
+69,457
New +$18.1M 0.82% 39

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

QVT Financial's MDGL Position: Q4 2013 in Review

QVT Financial sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2013, closing a stake of 50,008 shares — an estimated $11M sold.

QVT Financial first reported a position in MDGL in Q2 2013 and held it in 2 quarters. The position peaked at $12.1M in Q2 2013. 77 funds tracked by Wall St. Rank hold MDGL as of Q4 2013.

  • QVT Financial reported no remaining Madrigal Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • QVT Financial sold 50,008 Madrigal Pharmaceuticals shares in Q4 2013, an estimated $11M.
  • QVT Financial first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • QVT Financial's Madrigal Pharmaceuticals position peaked at $12.1M in Q2 2013.
  • 77 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2013.

Based on QVT Financial's 13F filing for Q4 2013, filed 18 Feb 2014.